Drug Trial Radar · NCT07810777
PRA-216 Atopic Dermatitis Safety and Efficacy Study
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
39
Planned (sponsor's estimate)
Start
Sep 17, 2026
Primary completion
Sep 30, 2027
Study completion May 16, 2028
Sponsor
- Lead sponsor
- Prana Therapies IncIndustry
- Sponsor type
- Industry
- First posted
- Sep 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with moderate to severe Atopic Dermatitis (AD)
Conditions
- Atopic Dermatitis (AD)
Interventions
Active PRA-216Drug
biologic
PlaceboDrug
matching placebo for PRA-216
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: Up to 28 weeks
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
Emeritus Sydney
Botany, New South Wales, Australia · Recruiting
Aperio Clinical Research
Liverpool, New South Wales, Australia · Not yet recruiting
Cornerstone Centre for Clinical Research
Coorparoo, Queensland, Australia · Recruiting
Emeritus Melbourne
Camberwell, Victoria, Australia · Not yet recruiting
Momentum Sunshine
Melbourne, Victoria, Australia · Not yet recruiting
Optimal Clinical Trials (North)
Auckland, New Zealand · Recruiting
Aotearoa Clinical Trials
Auckland, New Zealand · Recruiting
Momentum Christchurch
Christchurch, New Zealand · Recruiting
Clinical Trials New Zealand
Hamilton, New Zealand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.